Randomized study of bevacizumab/Tarceva [erlotinib] and Tarceva/Sulindac in squamous cell carcinoma of the head and neck.
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2017
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab; Sulindac
- Indications Head and neck cancer
- Focus Therapeutic Use
- 24 Jan 2017 Status changed from completed to discontinued due to slow accrual.
- 12 Apr 2016 Status changed from active, no longer recruiting to completed.
- 06 Mar 2012 Planned end date changed from 1 Oct 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov